Rubric Capital Management (New York)’s Arbutus Biopharma ABUS Stock Holding History

Rubric Capital Management (New York)’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.8M	Buy	6,626,389 +5,051,013	+321%	+$22.1M	0.32%	57
2025 Q4	$7.58M	Hold	1,575,376	–	–	0.09%	70
2025 Q3	$7.15M	Hold	1,575,376	–	–	0.08%	66
2025 Q2	$4.87M	Sell	1,575,376 -105,714	-6%	-$351K	0.07%	60
2025 Q1	$5.87M	Hold	1,681,090	–	–	0.11%	56
2024 Q4	$5.5M	Hold	1,681,090	–	–	0.07%	60
2024 Q3	$6.47M	Hold	1,681,090	–	–	0.11%	55
2024 Q2	$5.19M	Buy	+1,681,090	New	+$5.04M	0.14%	61
2023 Q3	–	Sell	-3,395,855	Closed	-$7.81M	–	62
2023 Q2	$7.81M	Sell	3,395,855 -799,217	-19%	-$2.08M	0.33%	51
2023 Q1	$12.7M	Buy	4,195,072 +728,791	+21%	+$2.06M	0.33%	51
2022 Q4	$8.08M	Buy	+3,466,281	New	+$8.29M	0.35%	61

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Rubric Capital Management (New York)'s ABUS Position: Q1 2026 in Review

Rubric Capital Management (New York) increased its Arbutus Biopharma (ABUS) stake by 321% in Q1 2026, buying an estimated $22.1M and bringing the position to 6,626,389 shares worth $29.8M. The position accounts for 0.32% of the portfolio, ranked #57.

Rubric Capital Management (New York) first reported a position in ABUS in Q4 2022 and has held it in 11 quarters since. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Rubric Capital Management (New York) held 6,626,389 shares of Arbutus Biopharma worth $29.8M as of Q1 2026.
Rubric Capital Management (New York) bought 5,051,013 Arbutus Biopharma shares in Q1 2026, an estimated $22.1M.
Arbutus Biopharma made up 0.32% of Rubric Capital Management (New York)'s portfolio in Q1 2026, its #57 holding.
Rubric Capital Management (New York) first reported a position in Arbutus Biopharma in Q4 2022 and has held it in 11 quarters since.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2026, filed 15 May 2026.